RELIEF THERAPEUTICS Holding SA - ESG Rating & Company Profile powered by AI
If you work at RELIEF THERAPEUTICS Holding SA and you would like to use your Sustainability aseessment, please get in touch. Complete Sustainability analysis of RELIEF THERAPEUTICS Holding SA can be reached by signing up for free. This assessment of RELIEF THERAPEUTICS Holding SA was prepared by All Street Sevva using advanced artificial intelligence.
RELIEF THERAPEUTICS Holding SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.3; made up of an environmental score of 2.0, social score of 1.6 and governance score of 3.2.
2.3
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1512 | Sol Gel Technologies Ltd | 2.4 | Medium |
1512 | Windtree Therapeutics Inc | 2.4 | Medium |
1529 | RELIEF THERAPEUTICS Holding SA | 2.3 | Medium |
1529 | ANI Pharmaceuticals Inc | 2.3 | Medium |
1529 | Aarti Drugs Ltd | 2.3 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does RELIEF THERAPEUTICS Holding SA have an accelerator or VC vehicle to help deliver innovation?
Does RELIEF THERAPEUTICS Holding SA disclose current and historical energy intensity?
Does RELIEF THERAPEUTICS Holding SA report the average age of the workforce?
Does RELIEF THERAPEUTICS Holding SA reference operational or capital allocation in relation to climate change?
Does RELIEF THERAPEUTICS Holding SA disclose its ethnicity pay gap?
Does RELIEF THERAPEUTICS Holding SA disclose cybersecurity risks?
Does RELIEF THERAPEUTICS Holding SA offer flexible work?
Does RELIEF THERAPEUTICS Holding SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does RELIEF THERAPEUTICS Holding SA disclose the number of employees in R&D functions?
Does RELIEF THERAPEUTICS Holding SA conduct supply chain audits?
Does RELIEF THERAPEUTICS Holding SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does RELIEF THERAPEUTICS Holding SA conduct 360 degree staff reviews?
Does RELIEF THERAPEUTICS Holding SA disclose the individual responsible for D&I?
Does RELIEF THERAPEUTICS Holding SA disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does RELIEF THERAPEUTICS Holding SA disclose current and / or historical scope 2 emissions?
Does RELIEF THERAPEUTICS Holding SA disclose water use targets?
Does RELIEF THERAPEUTICS Holding SA have careers partnerships with academic institutions?
Did RELIEF THERAPEUTICS Holding SA have a product recall in the last two years?
Does RELIEF THERAPEUTICS Holding SA disclose incidents of discrimination?
Does RELIEF THERAPEUTICS Holding SA allow for Work Councils/Collective Agreements to be formed?
Has RELIEF THERAPEUTICS Holding SA issued a profit warning in the past 24 months?
Does RELIEF THERAPEUTICS Holding SA disclose parental leave metrics?
Does RELIEF THERAPEUTICS Holding SA disclose climate scenario or pathway analysis?
Does RELIEF THERAPEUTICS Holding SA disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does RELIEF THERAPEUTICS Holding SA disclose the pay ratio of women to men?
Does RELIEF THERAPEUTICS Holding SA support suppliers with sustainability related research and development?
Does RELIEF THERAPEUTICS Holding SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does RELIEF THERAPEUTICS Holding SA reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is RELIEF THERAPEUTICS Holding SA involved in embryonic stem cell research?
Does RELIEF THERAPEUTICS Holding SA disclose GHG and Air Emissions intensity?
Does RELIEF THERAPEUTICS Holding SA disclose its waste policy?
Does RELIEF THERAPEUTICS Holding SA report according to TCFD requirements?
Does RELIEF THERAPEUTICS Holding SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does RELIEF THERAPEUTICS Holding SA disclose energy use targets?
Does RELIEF THERAPEUTICS Holding SA disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does RELIEF THERAPEUTICS Holding SA have a policy relating to cyber security?
Have a different question?
Potential Risks for RELIEF THERAPEUTICS Holding SA
These potential risks are based on the size, segment and geographies of the company.
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.